Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ERCC1
REST API REST API
Homo sapiens
ERCC1 is differentially expressed in 339 experiments: 143 organism parts: heart, cerebellum, ... (141 more);, 173 disease states: normal, control, ... (171 more);, 111 cell types 447 cell lines 45 compound treatments and 83 other conditions.
Synonyms RAD10
Orthologs Ercc1 (Rattus norvegicus)   ercc1 (Danio rerio)   ERCC1_BOVIN (Bos taurus)   Ercc1 (Mus musculus)   RAD10 (Saccharomyces cerevisiae)   Ercc1 (Drosophila melanogaster)   ercc1 (Xenopus laevis)   ENSCAFG00000023351 (Canis familiaris)   ENSCAFG00000004448 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term oogenesis, response to oxidative stress, DNA binding, nucleotide-excision repair, protein binding, DNA repair, cytoplasm, cell proliferation, damaged DNA binding, negative regulation of apoptosis, spermatogenesis, male gonad development, protein domain specific binding, multicellular organismal aging, single-stranded DNA binding, double-strand break repair, response to abiotic stimulus, nuclear chromosome, telomeric region, multicellular organism growth, response to nutrient, nucleus, DNA recombination, germ cell development, hydrolase activity, endonuclease activity, protein C-terminus binding, nucleoplasm, response to DNA damage stimulus, response to X-ray, chromosome organization, embryonic organ development, syncytium formation, post-embryonic hemopoiesis, transcription-coupled nucleotide-excision repair, negative regulation of telomere maintenance, nucleotide-excision repair complex, pyrimidine dimer repair by nucleotide-excision repair, structure-specific DNA binding, UV protection, isotype switching, nucleotide-excision repair, DNA incision, 3'-to lesion, nucleotide-excision repair, DNA incision, 5'-to lesion, cell development, single-stranded DNA specific endodeoxyribonuclease activity, replicative cell aging, response to sucrose stimulus, mitotic recombination, nucleotide-excision repair, DNA damage removal
InterPro Term HhH_motif, DNA_repair_Rad10
UniProt Accession Q8WWH8, P07992, Q96S40, B3KRR0, Q7Z7F5, F5GWP0
Gene-Disease Assocation CEREBROOCULOFACIOSKELETAL SYNDROME 4; COFS4
Search EB-eye ENSG00000012061
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-7224, E-GEOD-7540, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
SW480
3
E-GEOD-2509, E-GEOD-18005, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
HCC2157
2
E-MTAB-37, E-MTAB-62
HCC38
2
E-MTAB-37, E-MTAB-62
Jurkat
2
E-GEOD-1880, E-MEXP-2197
MOLT4
2
E-MTAB-62, E-MTAB-37
441 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
macrophage
3
E-GEOD-360, E-GEOD-3982, E-GEOD-22373
CD8+ T cell
3
E-AFMX-5, E-TABM-145, E-GEOD-6740
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
CD34+
2
E-AFMX-5, E-TABM-145
dendritic cell
2
E-GEOD-360, E-GEOD-3982
1
2
E-TABM-145, E-TABM-130
105 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (58 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MEXP-2034, E-MTAB-62, E-GEOD-96, E-MEXP-1327
control
1
4
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-20602, E-GEOD-3185 ... (5 experiments)
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
chronic myelogenous leukemia
1
E-MTAB-37
mesothelioma
1
E-MTAB-37
167 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (32 experiments)

Factor Value U/D Experiments
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
none
6
7
E-GEOD-5824, E-MEXP-1958, E-MEXP-1230, E-GEOD-7400, E-GEOD-412, ... (13 experiments)
1mM GDC-0941
1
1
E-GEOD-20719
unknown
1
E-GEOD-7307
M-CSF
1
E-GEOD-5099
39 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-2191, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-4667, E-MTAB-62

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-2509, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-GEOD-18005, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, ... (18 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (40 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, ... (7 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-6434, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-22541, E-GEOD-6532, E-GEOD-4922 ... (5 experiments)

Processing time: 0.307 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM